Pfizer

Pfizer (NYSE: PFE) is expected to formally announce Thursday a $210 million partnership with Zacharon Pharmaceuticals. The collaboration is centered around Zacharon's work in developing treatments for genetic diseases known as “lysosomal storage disorders”. This partnership marks the first such...

Goldman Sachs' long-held position that US pharma should get smaller through portfolio rationalizing is further supported by Pfizer Inc.'s (NYSE: PFE) new CEO's announcement to consider breakups or spin-offs of some or all of its business units. “We believe that if PFE were to lead the industry to...

If Star Scientific's (NASDAQ: CIGX) press release is to be believed, we might be on the precipice of a genuine breakthrough. James Altucher took a moment to translate the confusing and unusually written press release into what he calls “Investor-English.” His conclusion is that Star Scientific has...

In its look at Pfizer, Inc.'s (NYSE: PFE) product trends for the week ending 2-11-11, Citi reports on the following: “Lipitor NRx/TRx Share Was 20.9% (+2bps)/21.1% (-5bps),” Citi writes. “Lipitor NRx's/TRx's were 395,147 (-2% seq)/1,149,627 (-4%), rolling 4wk/12wk NRx's were down - 9%/-8%; TRxs -5...

Deutsche Bank has published a "company update" on Pfizer Inc. (NYSE: PFE) after the company displayed results due to forced R&D fund cutting as suggested by Deutsche Bank in November 2009. In the report, Deutsche Bank writes "We are raising our price target on PFE from $20 to $23, based upon a...

Deutsche Bank has raised the price target on Pfizer, Inc. (NYSE: PFE) from $20 to $23 and maintains its Buy rating.

Pfizer (NYSE: PFE) CEO Ian Read has his hands full, as Pfizer looks for ways to increase its stock's value with patents set to expire on many of its key drugs. Buybacks and asset divestitures are a couple of options for ways to enhance the value of Pfizer stock. Pfizer has begun buying back stock...

Pfizer (NYSE: PFE) announced the retirement of Chairman/CEO Jeff Kindler and his replacement as CEO by Ian Read, who was previously the company's head of biopharmaceuticals, J.P. Morgan reports. “Although Kindler was a controversial figure with the Street, his departure is unexpected,” J.P. Morgan...

In an update published yesterday, Citi has rated Pfizer (NYSE: PFE) High Risk. PFE is losing their base business in the US and has a negative US cash flow position. Other risks Citi mentions to PFE's price target are, "1) greater-than-expected financial and operational challenges relating to the...

In a report focusing on the synergies that could drive Pfizer, Inc. (NYSE: PFE) performance, Citigroup listed the following key issues and opportunities: 1) apixaban NDA filing by late 2010/early 2011 with the AVEEROS data 2) First Ph-III trial results for tasocitinib (JAK3; rheumatoid arthritis)...

Citigroup has released its Pfizer, Inc. (NYSE: PFE) core product trends for the week ending 10/15/2010. Lipitor, Lyrica, Chantix and AriceptXR are among the drugs featured in the report. “We arrive at our $17 target price for Pfizer based on a relative P/E compared to the US Drug peer group,”...

Bloomberg is reporting that Pfizer, Inc. (NYSE: PFE) has agreed to pay $3.6 billion in cash to buy King Pharmaceuticals, Inc. (NYSE: KG). The deal will cost Pfizer $14.25 per share – a 40% premium over yesterday's closing price. Bloomberg says that Pfizer needs new products to help offset the...

Citigroup has issued a report on Pfizer's (NYSE: PFE) product trends for the week ending on 9/24. In the report, Citigroup writes "Lipitor NRx/TRx Share Was 21.5%(-5bps)/22.0%(-15bps). Lipitor YOY TRx's have declined -12% YTD. PFE took 5% & 6.9% price increases(PI's) on 7/1/10 & 1/1/10...

Citigroup has published a research report for Pfizer, Inc. (NYSE: PFE). In the report, Citigroup writes "We rate the shares of Pfizer Hold/High Risk (2H). Declining volumes for its pharmaceutical products, a substantial 2010-‘13 period of generic risk, coupled with a limited late stage pipeline are...

CryoPort, Inc. (OTCBB: CYRX) today announced that it has named Michael Bartholomew as Chief Commercialization Officer. Mr. Bartholomew has 20 years experience in marketing, sales and sales management in the pharmaceuticals and materials industries. “Michael has an outstanding track record of...